64Cu-NOTA-Nb6 (Novamab Biopharmaceuticals)

64Cu-NOTA-Nb6（洛启生物）

Report date: 2025/11/07 11:34:15

Base Information

Drug Name64Cu-NOTA-Nb6 (Novamab Biopharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Diagnostic agent (In vivo)Radiation-emitting products > Nuclides > Copper > 64Cu +[6]

Mechanisms of ActionAnti-Programmed death-ligand 1

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsDiagnostic agentsLung Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd

Inactive CompaniesN/A

Active IndicationsDiagnostic agentsLung Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A